Michel Robidoux's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
President & Chief Executive Officer
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
"In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Health Canada regarding regulation about Requirement for reporting of drug shortages.
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
Health Canada regarding regulation about Requirement for reporting of drug shortages.
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.
Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.
Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.
Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program
Health Canada regarding regulation about Requirement for reporting of drug shortages.
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
Amend Bill C-64 to remove the risks and uncertainty that would undermine the stability and affordability of Canada's drug supply.
As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.
Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis
Economic DevelopmentHealth
Health
Economic DevelopmentHealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.